NCT03860038 is a Phase 2 clinical trial of TJ202 and Dexamethasone in Multiple Myeloma in Relapse, sponsored by TJ Biopharma Co., Ltd..

Who is sponsoring NCT03860038?

NCT03860038 is sponsored by TJ Biopharma Co., Ltd..

What drugs are being tested in NCT03860038?

Interventions in NCT03860038: TJ202 and Dexamethasone.

What condition does NCT03860038 study?

NCT03860038 studies Multiple Myeloma in Relapse, Refractory Multiple Myeloma.

Is NCT03860038 still recruiting?

NCT03860038 is currently completed. Last updated 24 April 2025.

Last reviewed 2025-04-24 · How we verify

NCT03860038

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Completed Phase 2 Last updated 24 April 2025

What this trial tests

Phase 2 trial testing TJ202 and Dexamethasone in Multiple Myeloma in Relapse in 113 participants. Completed in 28 January 2023.

Timeline

28 January 2019

Primary endpoint
28 January 2023

28 January 2023

Quick facts

Lead sponsor	TJ Biopharma Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	113
Start date	28 January 2019
Primary completion	28 January 2023
Estimated completion	28 January 2023
Sites	18 locations across China, Taiwan

Drugs / interventions tested

TJ202 and Dexamethasone — full drug profile →

Conditions studied

Multiple Myeloma in Relapse — all drugs for Multiple Myeloma in Relapse →
Refractory Multiple Myeloma — all drugs for Refractory Multiple Myeloma →

Sponsor

TJ Biopharma Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Multiple Myeloma in Relapse or Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is a multi-center, single-arm phase 2 study to evaluate the efficacy and safety of TJ202 combined with dexamethasone in subjects with relapsed or refractory multiple myeloma (RRMM) who received at least 2 prior lines of treatment.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Antibodies to watch in 2021.
Kaplon H, Reichert JM. · · 2021 · cited 215× · PMID 33459118 · DOI 10.1080/19420862.2020.1860476
Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next?
Tannoury M, Garnier D, Susin SA, Bauvois B. · · 2022 · cited 10× · PMID 36551511 · DOI 10.3390/cancers14246026
Antibody-Based Treatment Approaches in Multiple Myeloma.
Hosoya H, Sidana S. · · 2021 · cited 10× · PMID 33730360 · DOI 10.1007/s11899-021-00624-6
Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti-CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study.
Rovin BH, Boxhammer R, Thakur A, Ronco PM. · · 2022 · cited 6× · PMID 35702397 · DOI 10.1016/j.ekir.2022.05.031

Verify or expand the search:

Other recruiting trials for Multiple Myeloma in Relapse

Currently open trials in the same condition.

NCT07096778 — Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT06822972 — HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM · Phase 2 · recruiting
NCT07032129 — Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
NCT07248176 — Universal CAR-T Cell Therapy for MM · NA · recruiting
NCT06846905 — Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma. · recruiting

Other TJ Biopharma Co., Ltd. trials

Trials by the same sponsor.

NCT07453004 — A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With · Phase 2 · recruiting
NCT07208058 — A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/ · Phase 3 · recruiting
NCT07005336 — A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in · Phase 2 · active not recruiting
NCT06984588 — A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Pati · Phase 2, PHASE3 · active not recruiting
NCT06285201 — Study of Felzartamab in Healthy Adult Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03860038 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TJ Biopharma Co., Ltd.
Last refreshed: 24 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03860038.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing